Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
- 8 October 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 128 (15), 1656-1666
- https://doi.org/10.1161/circulationaha.113.003187
Abstract
Background— Emerging studies suggest that early administration of dual antiplatelet therapy may be better than monotherapy for prevention of early recurrent stroke and cardiovascular outcomes in acute ischemic stroke and transient ischemic attack (TIA). We performed a meta-analysis of randomized, controlled trials evaluating dual versus mono antiplatelet therapy for acute noncardioembolic ischemic stroke or TIA. Methods and Results— We assessed randomized, controlled trials investigating dual versus mono antiplatelet therapy published up to November 2012 and the CHANCE trial (Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events), for efficacy and safety outcomes in adult patients with acute noncardioembolic ischemic stroke or TIA with treatment initiated within 3 days of ictus. In total, 14 studies of 9012 patients were included in the systematic review and meta-analysis. Dual antiplatelet therapy significantly reduced risk of stroke recurrence (risk ratio, 0.69; 95% confidence interval, 0.60–0.80; PPP=0.37). Analyses restricted to the CHANCE Trial or the 7 double-blind randomized, controlled trials showed similar results. Conclusions— For patients with acute noncardioembolic ischemic stroke or TIA, dual therapy was more effective than monotherapy in reducing risks of early recurrent stroke. The results of the CHANCE study are consistent with previous studies done in other parts of the world.Keywords
This publication has 28 references indexed in Scilit:
- Risk and Cumulative Risk of Stroke RecurrenceStroke, 2011
- Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic AttackStroke, 2011
- Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysisBMC Medicine, 2010
- Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008Cerebrovascular Diseases, 2008
- Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysisThe Lancet Neurology, 2007
- Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparisonThe Lancet, 2007
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2006
- Recurrent stroke and cardiac risks after first ischemic strokeNeurology, 2006
- Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trialThe Lancet, 2004
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002